The Dopamine B-Hydroxylase 19 Bp Insertion/deletion Polymorphism Was Associated with First-Episode but Not Medicated Chronic Schizophrenia.

Li Hui,Xuan Zhang,Xu Feng Huang,Mei Han,Francesca Fernandez,Yaqin Yu,ShiLong Sun,Wenjun Li,Da Chun Chen,Mei Hong Xiu,Thomas R. Kosten,Xiang Yang Zhang
DOI: https://doi.org/10.1016/j.jpsychires.2012.02.016
IF: 5.25
2012-01-01
Journal of Psychiatric Research
Abstract:Background: Numerous studies report dysfunctional dopaminergic and noradrenergic neurotransmission in the pathogenesis of schizophrenia. Dopamine beta-hydroxylase (DBH) is an intracellular enzyme catalyzing the conversion of dopamine to noradrenaline. Functional polymorphisms have been reported in the promoter region of DBH gene, including a 19 bp insertion/deletion polymorphism. The purpose of this study was to investigate whether there was an association between the functional polymorphism (DBH5'-Ins/Del) and schizophrenia in a Han Chinese population.Methods: This polymorphism was genotyped in 221 first-episode schizophrenics, 360 chronic schizophrenics and 318 healthy controls using a case-control design. We assessed their psychopathology using the Positive and Negative Syndrome Scale (PANSS).Results: We showed that the DBH5'-Ins/Del deletion (Del) allelic and genotypic frequencies were significantly lower in controls than first-episode of schizophrenics (FES) (both p < 0.001), but controls were not different from chronic schizophrenics. Furthermore, the PANSS positive symptom and total scores were significantly higher in FES with the Del/Del genotype than those with Ins/Del and Ins/Ins genotypes (all p < 0.05).Conclusions: The DBH5'-Ins/Del polymorphism may play a role in susceptibility to the positive symptoms of FES and to these FES not progressing on to chronic schizophrenia. (C) 2012 Elsevier Ltd. All rights reserved.
What problem does this paper attempt to address?